Back

Monocytes promote intraepithelial infiltration of effector memory CD8+ T cells in regressing tumors

Vermare, A.; Ventura, A.; Rouault Montecino, A.; Simula, L.; Seradj, M.; Lhuillier, L.; Weber-Delacroix, E.; Mulder, K.; Vimeux, L.; Espie, D.; Bailly, K.; Izac, B.; Saintpierre, B.; Zeitouni, W.; Jolly, A.; Delagrange, P.; Guerin, M. v.; Donnadieu, E.; Pendino, F.; Dutertre, C.-A.; Boissonnas, A.; Prevost-Blondel, A.; Peranzoni, E.; Bercovici, N.

2026-05-29 immunology
10.64898/2026.05.28.728475 bioRxiv
Show abstract

Despite the clinical success of cancer immunotherapies, the cellular interactions driving tumor regression remain incompletely understood. Here, we investigated the dynamic remodeling of the tumor immune microenvironment during regression of transplanted PyMT mammary tumors following STING agonist treatment. Using scRNA-seq of sorted CD8+ T cells and myeloid cells, combined with imaging approaches, we identified major changes in both lymphoid and myeloid compartments during tumor regression. Regressing tumors showed a transient accumulation of Ly6Chi monocyte populations associated with a decline in macrophage subsets, while effector and memory CD8+ T-cell populations increased at the expense of exhausted T cells. Interaction analyses predicted enhanced chemotactic and adhesion interactions between CXCL9+ Ly6Chi monocytes and effector CD8+ T cells. Consistently, dynamic imaging revealed increased CD8+ T-cell motility and infiltration into tumor cores following treatment. In particular, CXCR6+ effector CD8+ T cells transiently accumulated within tumor islets during regression before relocalizing to stromal regions. Together, these findings reveal a coordinated spatiotemporal remodeling of myeloid and CD8+ T-cell populations during immunotherapy-induced tumor regression and highlight cooperative interactions that may promote durable anti-tumor immunity.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 7%
17.9%
2
Immunity
58 papers in training set
Top 0.5%
9.7%
3
Nature Immunology
71 papers in training set
Top 0.2%
6.9%
4
Journal of Experimental Medicine
106 papers in training set
Top 0.3%
6.6%
5
Science Immunology
81 papers in training set
Top 0.2%
6.6%
6
Cell Reports
1338 papers in training set
Top 8%
6.1%
50% of probability mass above
7
Cancer Immunology Research
34 papers in training set
Top 0.1%
6.1%
8
Nature Cancer
35 papers in training set
Top 0.4%
3.0%
9
Cell Reports Medicine
140 papers in training set
Top 2%
2.6%
10
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.4%
2.5%
11
Journal of Clinical Investigation
164 papers in training set
Top 2%
2.3%
12
Cancer Discovery
61 papers in training set
Top 0.9%
2.3%
13
Cell
370 papers in training set
Top 11%
1.7%
14
Cell Systems
167 papers in training set
Top 8%
1.6%
15
Nature
575 papers in training set
Top 12%
1.6%
16
Science Advances
1098 papers in training set
Top 21%
1.4%
17
eLife
5422 papers in training set
Top 48%
1.3%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 39%
1.2%
19
Science Translational Medicine
111 papers in training set
Top 4%
1.2%
20
Cancer Cell
38 papers in training set
Top 2%
0.9%
21
Nature Biotechnology
147 papers in training set
Top 8%
0.7%
22
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.6%
23
Cell Metabolism
49 papers in training set
Top 3%
0.6%
24
Genome Medicine
154 papers in training set
Top 10%
0.6%